Letter to the Editor

http://dx.doi.org/10.5021/ad.2015.27.4.474

Mutations in *EDA* and *EDAR* Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia

Julio C Salas-Alanis^{1,2}, Eva Wozniak³, Charles A Mein³, Carola C Duran Mckinster⁴, Jorge Ocampo-Candiani¹, David P Kelsell⁵, Rong Hua⁶, Maria L Garza-Rodriguez⁷, Keith A Choate⁶, Hugo A Barrera Saldaña^{7,8}

¹Dermatology Department, Hospital Universitario, Universidad Autonoma de Nuevo Leon,

²Basic Science Department, Medicine School, Universidad de Monterrey, Monterrey, NL, Mexico,

³Barts and the London Genome Centre, John Vane Science Centre, Barts and the London School of Medicine and Dentistry,

University of London, London, United Kingdom, ⁴Instituto Nacional de Pediatria, Coyoacan, CP, Mexico,

⁵Centre for Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry,

Queen Mary University of London, London, United Kingdom, ⁶Departments of Dermatology, Genetics, and Pathology,

Yale University School of Medicine, New Haven, CT, USA, ⁷Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular,

Universidad Autonoma de Nuevo Leon,⁸Vitagenesis, Monterrey, NL, Mexico

Dear Editor:

Ectodermal dysplasias (ED) encompass nearly 200 different genetic conditions identified by the lack, or dysgenesis, of at least two ectodermal derivatives, such as hair, nails, teeth, and sweat glands. Hypohidrotic/anhidrotic ED (HED) is the most frequent form of ED and it can be inherited as an X-linked (XL)-HED (MIM 305100), autosomal recessive (AR)-HED (MIM 224900), or autosomal dominant (AD)-HED (MIM 229490) condition. HED is caused by mutations in any of the three ectodisplasin pathway genes: ectodisplasin (*EDA*), which encodes a ligand for the second gene, the EDA receptor (ectodysplasin A-receptor, *EDAR*), and *EDARADD*, an intracellular signaling for this pathway. HED is characterized by a triad of clinical features including absent or diminished eccrine sweat glands, missing and/or malformed teeth, and thin, sparse hair. It also includes dryness of the skin, eyes, airways, and mucous membranes, as well as other ectodermal defects and, in some cases, fever, seizures, and rarely, death.

XL-HED is caused by mutations in the *EDA* gene, located on chromosome Xq12-q13.1, which encodes a signaling molecule of the tumor necrosis factor (TNF) superfamily. AR- and AD-HED are caused by mutations in the *EDAR* gene, located on chromosome 2q11.q13 or the EDAR-Associated Death Domain encoding gene, *EDARADD*, located on chromosome 1q42-q43¹.

Several mutations in the *EDA*, *EDAR*, and *EDARADD* genes have been described as causing HED in different populations. The XL-HED form is the most common and is responsible for 90% of all HED cases²⁻⁶.

The three forms of HED are clinically indistinguishable. To date, a comprehensive evaluation of HED in the Mexican Hispanic population has not been undertaken. In the present study, we aimed to characterize the mutations in *EDA*, *EDAR*, and *EDARADD* genes present in Mexican Hispanic patients with HED.

Male and female patients (35 families) from different geographical regions of Mexico with features suggestive of HED were enrolled in the study (Fig. 1). Index cases and their parents were screened for missing or malformed teeth, thin or sparse hair, and nail changes; all subjects answered questions about sweating, heat intolerance, fever, seizures, and family history of siblings deceased due to unknown fever

Received July 7, 2014, Revised September 12, 2014, Accepted for publication September 19, 2014

Corresponding author: Keith A Choate, Departments of Dermatology, Genetics, and Pathology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA. Tel: 1-203-785-3912, Fax: 1-888-480-780, E-mail: keith.choate@yale.edu

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.







p.C346W

p.C346Y

p.E128Ter

p.G350D

p.E15OK

p.T378M

p.R155C

p.12codondel

p.G192R

c.793+1 G>C

p.Y304C



Het/p.C71Y

Fig. 1. Mutations in ectodisplasin (*EDA*) and ectodysplasin A-receptor (*EDAR*) genes cause hypohidrotic/anhidrotic ED (HED). (A) Index case (arrow) from X-linked pedigree shows multiple male affected offspring. Two of them died of fever during the first month of birth. Mutation analysis revels a homozygous c.1049G > A, p.G350D mutation. Male and female index cases (arrows) from a family with Autosomal Recessive HED. This patient has an heterozygous mutation in Exon 3 c.212 G > A, p.71 C > Y. The clinical findings of these two patients with HED show a sparse hair, frontal bossing, saddle nose, periocular hyperpigmentation and enlarged lips are evident. In our cohort there was no difference between the two forms of inheritance. White symbols indicate unaffected individuals, black squares and circles denote affected, dots indicate obligate carried females, the propositus are in arrows. (B) X-linked-HED, clinical variability in male patients analayzed. They show the clasical triad of HED, dental abnormalities, anhidrosis/hypohirosis and thin sparse hair. Some of them has normal hair appaerance and recessive HED female patient with minor clinical aspect of HED.

during the first year of life.

The protocol was approved by the ethics and research committees of the University Hospital of the Autonomous University of Nuevo Leon (DE 12-007) and Yale University School of Medicine. After obtaining informed consent, peripheral blood of patients and family members was drawn and DNA was extracted using a standard phenol-chloroform protocol.

All exons of *EDA*, *EDAR*, and *EDARADD* genes were screened using specific primers as described by Cluzeau et al.², 2011; polymerase chain reaction amplification was performed using Amplitaq Gold (Applied Biosystems, Foster City, CA, USA) or Kapa 2G Fast polymerase (Kapa Biosystems, Wilmington, MA, USA).

Sequencing reactions were carried out using Big Dye Terminator v3.1 (Applied Biosystems) and resulting DNA fragments were sequenced using the 3130xl Genetic Analyzer (Applied Biosystems). Sequencing quality control and assembly were performed using Sequence Scanner V.1.0 (Applied Biosystems) and Phred, Phrap, and Consed or Sequencher software (Gene Codes, Ann Arbor, MI, USA)⁷. A total of 40 patients from 35 families were tested for *EDA*, *EDAR*, and *EDARADD* mutations. Sequence analysis of all coding exons of *EDA*, *EDAR*, and *EDARADD* genes identified 16 different mutations in 21 (60%) families (Table 1)^{3,4,8-10}.

Sixteen different mutations were present; fifteen mutations were found in the *EDA* gene, 5 had previously been reported, and 10 were novel. One known mutation was found in the *EDAR* gene.

No mutations were found in the EDARADD gene in the

remaining kindreds (14) analyzed. WNT10A analysis was not performed.

Upon review of the clinical features in the affected patients and female carriers, there was no phenotypic correlation with genotype (data not shown). Ten obligate female carriers displayed dental abnormalities (one missing tooth) that were independent of specific mutations; we speculate that this may be due to random X-inactivation.

In studying a Mexican Hispanic Cohort (see results Table 1), we have found that 60% bear mutations in *EDA* or *EDAR*, but not in *EDARDD*. Of the 16 identified inherited mutations, ten were novel. Of these novel mutations in *EDA*, p.E36ter is a nonsense mutation that produces a truncated protein; the other nine missense mutations lie in conserved regions of the protein including the furin cleavage site and the TNF-like domain where previous disease-causing mutations have been identified. The nonsense mutations p.E36ter and p.Q128ter produce a truncated form of the ectodisplasin protein, subject to nonsense-mediated decay³. Missense mutations p.R150K, p.R155C, and p.R156H disrupt the furin cleavage site, whereas p.G299R, p.C346Y, p.C346W, and p.T378M are predicted to disrupt protein function⁴⁻⁶.

Two novel deletion mutations were present in this population: c.del 546-581 (p.183-194 del) and c.887-900 del, p.297-301delFSx4 as one splice site mutation, c.793+1 G > C.

Thirty-three mutations, mainly missense mutations, *EDAR* gene have previously been reported¹¹. We found a homozygous c.G212A, p.C70Y mutation in exon 3 of *EDAR* in

Exon	Coding sequence variant	Protein change	Mutation type	Reference
EDA-1	c.106G>T	p.E36Ter	Nonsense	
EDA-1	c.382C>T	p.Q128ter	Nonsense	Schneider et al. ³
EDA-3	c.448G>A	p.E150K	Missense	
EDA-3	c.463C>T	p.R155C	Missense	Vincent et al. ⁴
EDA-3	c.467G>A	p.R156H	Missense	Monreal et al. ⁹
EDA-4	c.Del 546-581	p.183-194del	Deletion	
EDA-5	c.574G>C	p.G192R	Missense	
EDA-6	c.793+1 G>C		Splice site	
ED-A7	Del 887-900	p.297-301delFSx4	Deletion	
EDA-8	c.894G>C	p.G299R	Missense	
EDA-8	c.911A>G	p.Y304C	Missense	RamaDevi et al. ¹⁰
EDA-9	c.1037G>A	p.C346Y	Missense	
EDA-9	c.1038C>G	p.C346W	Missense	
EDA-9	c.1049G>A	p.G350D	Missense	
EDA-9	c.1133C>T	p.T378M	Missense	Schneider et al. ³
EDAR 3/11 AR-HED*	c.212 G>A	p.C71Y	Missense	Moya-Quiles et al. ⁸
	Exon EDA-1 EDA-1 EDA-3 EDA-3 EDA-3 EDA-3 EDA-4 EDA-5 EDA-6 ED-A7 EDA-6 ED-A7 EDA-8 EDA-8 EDA-8 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA-9 EDA	Exon Coding sequence variant EDA-1 c.106G>T EDA-1 c.382C>T EDA-3 c.448G>A EDA-3 c.463C>T EDA-3 c.463C>T EDA-3 c.463C>T EDA-3 c.463C>T EDA-3 c.463C>T EDA-3 c.467G>A EDA-4 c.Del 546-581 EDA-5 c.574G>C EDA-6 c.793+1 G>C EDA-7 Del 887-900 EDA-8 c.911A>G EDA-9 c.1037G>A EDA-9 c.1037G>A EDA-9 c.1049G>A EDA-9 c.1133C>T EDAR 3/11 AR-HED* c.212 G>A	Exon Coding sequence variant Protein change EDA-1 c.106G>T p.E36Ter EDA-1 c.382C>T p.Q128ter EDA-3 c.448G>A p.E150K EDA-3 c.463C>T p.R155C EDA-3 c.467G>A p.R156H EDA-3 c.467G>C p.G192R EDA-4 c.Del 546-581 p.183-194del EDA-5 c.574G>C p.G192R EDA-6 c.793 + 1 G>C EDA-7 EDA-8 c.894G>C p.G299R EDA-8 c.911A>G p.Y304C EDA-9 c.1037G>A p.C346W EDA-9 c.1049G>A p.G350D EDA-9 c.1133C>T p.T378M EDA-8 3/11 AR-HED* c.212 G>A p.C71Y	ExonCoding sequence variantProtein changeMutation typeEDA-1 $c.106G>T$ $p.E36Ter$ NonsenseEDA-1 $c.382C>T$ $p.Q128ter$ NonsenseEDA-3 $c.448G>A$ $p.E150K$ MissenseEDA-3 $c.463C>T$ $p.R155C$ MissenseEDA-3 $c.467G>A$ $p.R156H$ MissenseEDA-4 $c.Del 546-581$ $p.183-194del$ DeletionEDA-5 $c.574G>C$ $p.G192R$ MissenseEDA-6 $c.793+1$ $G>C$ Splice siteED-A7Del 887-900 $p.297-301delFSx4$ DeletionEDA-8 $c.911A>G$ $p.Y304C$ MissenseEDA-9 $c.1037G>A$ $p.C346W$ MissenseEDA-9 $c.1049G>A$ $p.G350D$ MissenseEDA-9 $c.1133C>T$ $p.T378M$ MissenseEDAR 3/11 AR-HED* $c.212$ $G>A$ $p.C71Y$ Missense

Table 1. Mutations identified in 35 Mexican Hispanic families with hypohidrotic ectodermal dysplasia (ED)

*Autosomic recessive hypohidrotic/anhidrotic ED (HED). *EDA* ten novel mutations are show in bold. Fifteen mutations in different domains of the *EDA* gene were found. Four non-related families have the same recurrent mutation p.G3650D in the tumor necrosis factor domain.

an affected father-daughter pair with AR HED. This mutation lies within the ligandbinding domain of EDAR and is crucial for binding to the ligand⁸. A novel recurrent mutation p.G350D was found in four kindred, and the previously reported p.R155C was found in three kindred³. This suggests possible independent founder mutations in the Mexican Hispanic population.

These first findings in the Mexican Hispanic population expand the mutation spectrum in *EDA* and *EDAR* in HED, and confirm the clinical diagnosis in a large cohort. Recurrent mutations suggest possible founder mutations that may aid in genetic counseling and prenatal diagnosis in at-risk pregnancies. We also found that newborn febrile seizures are a significant cause of perinatal lethality, with 8 deaths in our cohort. An additional benefit of our study is the identification of potential candidates for replacement therapy with recombinant EDA protein (Edimer Pharmaceuticals, Cambridge, MA, USA)¹².

REFERENCES

- 1. Visinoni AF, Lisboa-Costa T, Pagnan NA, Chautard-Freire-Maia EA. Ectodermal dysplasias: clinical and molecular review. Am J Med Genet A 2009;149A:1980-2002.
- 2. Cluzeau C, Hadj-Rabia S, Jambou M, Mansour S, Guigue P, Masmoudi S, et al. Only four genes (EDA1, EDAR, EDARADD, and WNT10A) account for 90% of hypohidrotic/anhidrotic ectodermal dysplasia cases. Hum Mutat 2011;32:70-72.
- 3. Schneider P, Street SL, Gaide O, Hertig S, Tardivel A, Tschopp J, et al. Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A.

J Biol Chem 2001;276:18819-18827.

- Vincent MC, Biancalana V, Ginisty D, Mandel JL, Calvas P. Mutational spectrum of the ED1 gene in X-linked hypohidrotic ectodermal dysplasia. Eur J Hum Genet 2001;9:355-363.
- Bashyam MD, Chaudhary AK, Reddy EC, Reddy V, Acharya V, Nagarajaram HA, et al. A founder ectodysplasin A receptor (EDAR) mutation results in a high frequency of the autosomal recessive form of hypohidrotic ectodermal dysplasia in India. Br J Dermatol 2012;166:819-829.
- Clauss F, Chassaing N, Smahi A, Vincent MC, Calvas P, Molla M, et al. X-linked and autosomal recessive Hypohidrotic Ectodermal Dysplasia: genotypic-dental phenotypic findings. Clin Genet 2010;78:257-266.
- Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175-185.
- Moya-Quiles MR, Ballesta-Martínez MJ, López-González V, Glover G, Guillén-Navarro E. A compound heterozygous mutation in the EDAR gene in a Spanish family with autosomal recessive hypohidrotic ectodermal dysplasia. Arch Dermatol Res 2010;302:307-310.
- Monreal AW, Zonana J, Ferguson B. Identification of a new splice form of the EDA1 gene permits detection of nearly all X-linked hypohidrotic ectodermal dysplasia mutations. Am J Hum Genet 1998;63:380-389.
- RamaDevi AR, Reddy EC, Ranjan S, Bashyam MD. Molecular genetic analysis of patients from India with hypohidrotic ectodermal dysplasia reveals novel mutations in the EDA and EDAR genes. Br J Dermatol 2008;158:163-167.
- Institute of Medical Genetics in Cardiff. The Human Gene Mutation Database (Internet). Cardiff: The Human Gene Mutation Database; 2014 [cited 2014 June 20]. Available from: http://www.hgmd.org.
- 12. Huttner K. Future developments in XLHED treatment approaches. Am J Med Genet A 2014;164A:2433-2436.